

IDS/#2
9/20/01

PATENT
Docket No. 500862000105
Client Ref. REDC-135

CERTIFICATE OF MAILING BY "EXPRESS MAIL"

Express Mail Label No.: EL209765426US

Date of Deposit: August 3, 2001

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. § 1.10 on the date indicated above and is addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231.


CHASE J. TROMBELLA

j1046 U.S. PTO
09/21/01



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Philippe POULETTY et al.

Serial No.: TO BE ASSIGNED

Filing Date: HERewith

For: REACTIVELY MODIFIED
THERAPEUTIC COMPOUNDS
HAVING AN EXTENDED LIFETIME
IN VIVO (AS AMENDED)

Examiner: TO BE ASSIGNED

Group Art Unit: 1641

**INFORMATION DISCLOSURE
STATEMENT UNDER 37 C.F.R. § 1.97**

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO-1449. Copies of the documents were previously submitted in an Information Disclosure Statement and/or Office Action, directed to the related application Serial Number 09/539,766, filed March 31, 2000, and, accordingly, copies are not included herewith. This protocol conforms with 37 C.F.R. §1.98(d)

and M.P.E.P. 609(A)(2). The Examiner is requested to make these documents of record in the application.

This Information Disclosure Statement is submitted:

- ☒ With the application; accordingly, no fee or separate requirements are required.
- ☐ Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required.
- ☐ After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance.
 - ☐ A fee is required. A check in the amount of * is enclosed.
 - ☐ A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below; accordingly; no fee is believed to be due.
- ☐ After mailing of a final Office Action or Notice of Allowance, but before payment of the issue fee. Accordingly, a Petition requesting consideration of the Information Disclosure Statement, an authorization to charge our deposit account, and a Certification under 37 C.F.R. § 1.97(e) are provided herein.

Applicants would appreciate the Examiner initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.

The information contained in this Information Disclosure Statement under 37 C.F.R. § 1.97 is to the best of my knowledge and is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, applicant petitions for any required relief including extensions of time and authorizes the Assistant Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing 500862000105. However, the Assistant Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: August 3, 2001

Respectfully submitted,

By: Michael R. Ward
Michael R. Ward
Registration No. (38,651)

Morrison & Foerster LLP
425 Market Street
San Francisco, California 94105-2482
Telephone: (415) 268-6237
Facsimile: (415) 268-7522

FORM PTO-1449 (Modified)
(Rev. 7-80)U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

Serial No.

500862000105

TBA

INFORMATION DISCLOSURE CITATION

Applicant(s)

PHILIPPE POULETTY ET AL.

Filing Date

Herewith

Group

1641

J1045 U.S. PTO
09/921663

08/03/01

U.S. PATENT DOCUMENTS

Examiner Initials	Document Number	Date	Name	Class	Sub- Class	Filing Date
AA	3,969,287	07/13/76	JAWOREK, ET AL	260	8	11/30/73
AB	4,634,762	01/06/87	FEIJEN, ET AL	530	350	03/26/85
AC	4,676,980	06/30/87	SEGAL, ET AL	424	85	09/23/85
AD	4,883,650	11/28/89	BHARGAVA, ET AL	424	1.1	04/13/88
AE	4,919,928	04/24/90	JANSEN, ET AL	424	85.91	04/06/87
AF	4,954,637	09/04/90	NITECKI, ET AL	548	546	09/10/87
AG	4,971,792	11/20/90	Steplewski, ET AL	424	85.91	03/27/87
AH	4,981,979	01/01/91	SIVAM	548	545	09/10/87
AI	5,061,750	10/29/91	FEIJEN, ET AL	525	54.1	07/18/90
AJ	5,112,615	05/12/92	ITO, ET AL	424	426	10/04/90
AK	5,116,944	05/26/92	SIVAM, ET AL	530	362	12/29/89
AL	5,169,933	12/08/92	ANDERSON, ET AL	530	391.3	08/07/89
AM	5,283,344	02/01/94	CHANG	548	546	03/10/93
AN	5,308,604	05/03/94	SINN, ET AL	424	1.53	03/26/92
AO	5,326,778	07/05/94	ROSEBROUGH	514	387	03/03/92
AP	5,328,840	07/12/94	COLLER	435	240.2	11/12/91
AQ	5,612,034	03/18/97	POULETTY, ET AL	424	184.1	05/03/94
AR	5,705,143	01/06/98	BOWER, ET AL	424	1.69	07/11/96
AS	5,843,440	12/01/98	Pouletty, ET AL	424	133.1	08/14/96
AT	5,906,977	05/25/99	SINN, ET AL	514	12	09/26/95

EXAMINER: _____

DATE CONSIDERED: _____

FORM PTO-1449 (Modified)
(Rev. 7-80)U.S. Dept. of Commerce
Patent and Trademark OfficeAtty Docket No.
500862000105Serial No.
TBA

INFORMATION DISCLOSURE CITATION

Applicant(s)
PHILIPPE POULETTY ET AL.Filing Date
HerewithGroup
1641

FOREIGN PATENT DOCUMENTS

Examiner Initials	Document Number	Date	Country	Class	Sub- Class	Translation	
						YES	NO
AU	EP 0 183 503 A2	06/04/86	European Patent Convention	C07K	17/06		X
AV	EP 0 395 918 A2	11/07/90	European Patent Convention	C12N	11/02		X
AW	EP 0 602 290 A1	06/22/94	European Patent Convention	A61K	47/48		X
AX	EP 0 323 806 A1	12/28/88	European Patent Convention	C12N	15/00		X
AY	GB 2 218 100A	08/11/89	United Kingdom	G01N	33/53		X
AZ	JP 59-138958	08/09/84	Japan	G01N	A61K		X
BA	JP 6-92968	04/05/94	Japan	C07D	195/04		X
BB	WO 90/14103	11/29/90	Patent Cooperation Treaty	A61K	39/395		X
BC	WO 92/01469	02/06/92	Patent Cooperation Treaty	A61K	39/00		X
BD	WO 96/090,71A1	03/28/96	Patent Cooperation Treaty	A61K	47/48		X

EXAMINER: _____

DATE CONSIDERED: _____

FORM PTO-1449 (Modified)
(Rev. 7-80)U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

Serial No.

500862000105

TBA

INFORMATION DISCLOSURE CITATION

Applicant(s)

PHILIPPE POULETTY ET AL.

Filing Date

Herewith

Group

1641

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, etc.)

- BE Bacon-Baguley, et al., THROMBOSPONDIN BINDING TO SPECIFIC SEQUENCES WITHIN THE A - AND B - CHAINS OF FIBRINOGEN
- BF Baranowska-Kortylewicz, et al. "5-Iodo-2'-Deoxyuridine-Protein Conjugates: Synthesis and Enzymatic Degradation", Selective Cancer Therapeutics, 1:6:1-14 (1990)
- BG Christian, et al., SENESENCE OF CANINE BIOTINYLATED ERYTHROCYTES: INCREASED AUTOLOGOUS IMMUNOGLOBULIN BINDING OCCURS ON ERYTHROCYTES AGED IN VIVO FOR 104 TO 110 DAYS, Blood 82(11):3469-3473 (1993)
- BH Collier, et al. THROMBOERYTHROCYTES - IN VITRO STUDIES OF A POTENTIAL AUTOLOGOUS, SEMI-ARTIFICIAL ALTERNATIVE TO PLATELET TRANSFUSIONS, J. Clin. Invest. 89:546-555 (1992)
- BI Collet, B., et al. "SCINTIGRAPHIC DETECTION IN MICE OF INFLAMMATORY LESIONS AND TUMOURS BY AN INDIUM-LABELLED MONOCLONAL ANTIBODY DIRECTED AGAINST MAC-1 ANTIGEN" Cancer Immun. Immunother 26:237-242 (1988)
- BJ Danilov, et al. (ARG-GLY-ASP)-ALBUMIN CONJUGATES AS A MODEL SUBSTRATE FOR INTEGRIN-MEDIATED CELL ADHESION Experimental Cell Research 182:186-196 (1989)
- BK Freud, A., et al. "A CONVENIENT SYNTHESIS OF N-SUCCINIMIDYL-3-iodo[125I]BENZOATE, A REAGENT FOR PROTEIN IODINATION", Nucl. Med. Biol. 19:(6):703-704 (1992) XP-002122856
- BL Gerig, et al., MODIFICATION OF HUMAN SERUM ALBUMIN WITH N-(2,5-DINITRO-4-FLUOROPHENYL)-4-AMINO-2,2,6,6-TETRAMETHYLPYPERIDINOXY RADICAL, Biochimica et Biophysica Acta 579:409-420 (1979)
- BM Ghose, et al. ANTIBODY-LINKED CYTOTOXIC AGENTS IN THE TREATMENT OF CANCER: CURRENT STATUS AND FUTURE PROSPECTS, J. Natl. Cancer Inst. 61(3):657-676 (1978)
- BN Gillies, et al. ANTIGEN BINDING AND BIOLOGICAL ACTIVITIES OF ENGINEERED MUTANT CHIMERIC ANTIBODIES WITH HUMAN TUMOR SPECIFICITIES, Hum. Antibod. Hybridomas, 1(1):47-54 (1990)
- BO Harris, et al. THERAPEUTIC ANTIBODIES - THE COMING OF AGE, JBTECH 11:42-44 (1993)
- BP Kemp, et al. AUTOLOGOUS RED CELL AGGLUTINATION ASSAY FOR HIV-1 ANTIBODIES: SIMPLIFIED TEST WITH WHOLE BLOOD, Science 241:1352-1354 (1988)
- BQ Kinsey, et al. EFFICIENT CONJUGATION OF DTPA TO AN IGM MONOCLONAL ANTIBODY IN ASCITES FLUID Nucl. Med. Biol. 15(3):285-292 (1988)
- BR Koolwijk, P., et al. "BINDING OF THE HUMAN COMPLEMENT SUBCOMPONENT C1q TO HYBRID MOUSE MONOCLONAL ANTIBODIES" Molecular Immun. 28:(6):567-576 (1991)
- BS Kurantsin-Mills, et al., INDIUM-111 OXINE LABELED ERYTHROCYTES: CELLULAR DISTRIBUTION AND EFFLUX KINETICS OF THE LABEL, Nucl. Med. Biol. 16(8):821-27 (1989)
- BT Lambert, et al. PURIFIED IMMUNOTOXINS CONJUGATED TO THE RIBOSOME-INACTIVATING PROTEINS GELONIN AND THE POKEWEED ANTIVIRAL PROTEINS, J. of Biological Chem. 260(22):12035-12041 (1985)
- BU Magnani, et al., PREPARATION AND CHARACTERIZATION OF BIOTINYLATED RED BLOOD CELLS, Biotechnol. Appl. Biochem. 20:335-45 (1994)
- BV Magnani, et al. RED BLOOD CELLS AS AN ANTIGEN-DELIVERY SYSTEM Biotechnology and Applied Biochemistry 16:188-194 (1992)
- BW Proulx, et al., A KIT FOR LABELLING ERYTHROCYTES OR LEUKOCYTES WITH TECHNETIUM-99M, Nucl. Med. Biol. 17(5):515-17 (1990)
- BX Samokhin, et al. RED BLOOD CELL TARGETING TO COLLAGEN-COATED SURFACES Institute of Experimental Cardiology, 154(2):257-261 (1983)

EXAMINER: _____

DATE CONSIDERED: _____

FORM PTO-1449 (Modified)
(Rev. 7-80)U.S. Dept. of Commerce
Patent and Trademark OfficeAtty Docket No.
500862000105Serial No.
TBA

INFORMATION DISCLOSURE CITATION

Applicant(s)
PHILIPPE POULETTY ET AL.Filing Date
HerewithGroup
1641

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, etc.)

- BY Schlom MONOCLONAL ANTIBODIES: THEY'RE MORE AND LESS THAN YOU THINK Molecular Foundations of Oncology 2(6):95-134 (1991)
- BZ Suzuki, et al., BIOTINYLATED ERYTHROCYTES: IN VIVO SURVIVAL AND IN VITRO RECOVERY, Blood (US) 70(3):791-95 (1987) Abstract (ISSN 0006-4971)
- CA Tao, et al. STUDIES OF AGLYCOSYLATED CHIMERIC MOUSE-HUMAN IgC, The J. of Immunology 143(8):2595-2601
- CB Taylor, et al., IN VIVO BINDING AND CLEARANCE OF CIRCULATING ANTIGEN BY BISPECIFIC HETEROPOLYMER-MEDIATED BINDING TO PRIMATE ERYTHROCYTE COMPLEMENT RECEPTOR, J. Immunol. 148(8):2462-68 (1992)
- CC Taylor, et al., USE OF HETEROPOLYMERIC MONOCLONAL ANTIBODIES TO ATTACH ANTIGENS TO THE C3b RECEPTOR OF HUMAN ERYTHROCYTES: A POTENTIAL THERAPEUTIC TREATMENT, Proc. Natl. Acad. Sci. USA, 88:3305-09 (1991)
- CD Titus, et al., HUMAN K/NATURAL KILLER CELLS TARGETED WITH HETERO-CROSS-LINKED ANTIBODIES SPECIFICALLY LYSE TUMOR CELLS IN VITRO AND PREVENT TUMOR GROWTH IN VIVO, J. Immunol. 139(9):3153-58 (1987)
- CE TRAIL, P.A., ET AL., "CURE OF XENOGRAFTED HUMAN CARCINOMAS BY BR96-DOXORUBICIN IMMUNOCONJUGATES", Science 261 212-215 (1993)
- CF Verbeke, K. et al., "FIRST EVALUATION OF TECHNETIUM-99m DIMERCAPTOPROPIONYL ALBUMIN AS A POSSIBLE TRACER AGENT FOR VENTRICULOGRAPHY IN A VOLUNTEER" European J. of Nucl. Med. 21:(9):906-912 (1994) Abstract: XP-002122855
- CG Waldmann, MONOCLONAL ANTIBODIES IN DIAGNOSIS AND THERAPY Science 252:1657-1662 (1991)
- CH Wilbur, D. Scott, "RADIOHALOGENATION OF PROTEINS: AN OVERVIEW OF RADIONUCLIDES, LABELING METHODS, AND REAGENTS FOR CONJUGATE LABELING" Bioconjugate Chem., 3:(6):433-470 (1992)
- CI Yokoyama, et al., DEFEROXAMINE, A PROMISING BIFUNCTIONAL CHELATING AGENT FOR LABELING PROTEINS WITH GALLIUM: Ga-67 DF-HSA: CONCISE COMMUNICATION, J. Nucl. Med. 23:909-14 (1982)

EXAMINER: _____

DATE CONSIDERED: _____

FORM PTO-1449 (Modified) (Rev. 7-80)		U.S. Dept. of Commerce Patent and Trademark Office		Atty Docket No. 500862000105		Application No. TBA	
INFORMATION DISCLOSURE CITATION				Applicant(s) Philippe Pouletty et al.		Group 1641	
(Use several sheets if necessary)				Filing Date HEREWITH			
U.S. PATENT DOCUMENTS							
*Examiner Initials		Document Number	Date	Name	Class	Subclass	Filing Date
	CJ	5,612,034	03/18/97	POULETTY	424	184.1	05/03/94
	CK	5,843,440	12/01/98	POULETTY, ET AL.	424	133.1	08/14/96
	CL	6,103,233	08/15/00	POULETTY, ET AL.	424	133.1	06/07/95
FOREIGN PATENT DOCUMENTS							
*Examiner Initials		Document Number	Date	Country	Class	Subclass	Translation YES NO
OTHER DOCUMENTS							
Examiner					Date Considered		
<p>* Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>							